



Practitioner Docket No. 211-US-NEW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 23 2000

TECH CENTER 1600/2900

In re Application of: )  
MOYER, Elizabeth, et al. )  
Application No.: 09/393,590 ) Group No.: 1645  
Filed: 09/09/99 ) Examiner: S. Devi  
For: STABLE LIQUID FORMULATIONS OF BOTULINUM )  
TOXIN )

Certificate of Mailing (37 C.F.R. § 1.8(a))

I hereby certify that, on the date shown below, this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231.

Date: 8/18/00

By: 

Assistant Commissioner for Patents  
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Supplemental Information Disclosure Statement

The following sections are being submitted for this Supplemental Information Disclosure Statement:

1. Preliminary Statements
2. Form PTO/SB/08B (formerly Form PTO-1449)
3. Statement as to Information Not Found in Patents or Publications

RECEIVED  
AUG 23 2001  
TECH CENTER 1600/2900

Section 1. **Preliminary statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

A copy of a search report issued by the European Patent Office in related case PCT/US99/20912 is enclosed. The references cited therein are included in the listing on form PTO/SB/08A.

Section 2. Form PTO/SB/08B (substitute for Form PTO-1449)



RECEIVED  
AUG 23 2008  
TECH CENTER 1600/2900

**Section 3. Statement as to Information Not Found in Patents or Publications (Information Not Listed in Forms PTO/SB/08A and 08B (substitute for Form PTO-1449)**

The formulation of the invention was supplied by applicants' assignee to certain clinical investigators for use in clinical trials prior to September 10, 1997. In order to participate in the clinical trials, each clinical investigator signed a clinical study agreement that included provisions to ensure confidentiality of any information or material provided to the investigator.



RECEIVED  
AUG 23 2000  
TECH CENTER 1600/2900



Date: 18 AUG 00

Reg. No. 35,195

Tel. No.: (650) 616-5035

Customer No.: 21835

Respectfully submitted,

J. Mark Hoch

SIGNATURE OF PRACTITIONER

J. Mark Hoch

Elan Pharmaceuticals, Inc.

800 Gateway Boulevard

South San Francisco, CA 94080